Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Drug touted by Trump to fight COVID-19 linked to cardiac issues, increased deaths

Ruchika Sharma18 May 2020 9:00 AM IST

Some drug safety experts are now calling for even more forceful action by the government to discourage its use

Hikal develops generic API of Avigan

Ruchika Sharma17 May 2020 12:00 PM IST

Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation

Bayer, Archer DX collaborate to develop NGS based Companion Diagnostic for VITRAKVI

Ruchika Sharma17 May 2020 11:15 AM IST

NGS-based CDx tests aim to unlock molecular information from each patient’s tumor genome to guide treatment decisions for cancer therapies

Sanofi gets USFDA priority review for sutimlimab for Hemolysis

Ruchika Sharma17 May 2020 11:00 AM IST

Paris: The U.S. Food and Drug Administration (FDA) has granted priority review of Sanofi's Biologics License Application (BLA) for sutimlimab for the...

Teva, 2 others sue Aurobindo Pharma for alleged infringement of cancer drug Bendeka

Ruchika Sharma17 May 2020 10:45 AM IST

Teva filed a probable patent infringement petition on May 11 against Aurobindo in the US district court for the District of Delaware on 28 counts.

Covid-19 Treatment: Russia sees promising results in early trials of Favipiravir

Ruchika Sharma17 May 2020 10:30 AM IST

Moscow: A candidate drug for treating the new coronavirus, Favipiravir, has produced promising results in early clinical trials in Russia, according...

Five companies added to MSCI India Index; four deleted

Ruchika Sharma17 May 2020 10:00 AM IST

New Delhi: A total of four companies, including Ashok Leyland and Tata Power Company, have been removed from the MSCI India Index, while there have...

COVID Antibody: Zydus Cadila gets nod for ICMR-NIV developed ELISA kit

Ruchika Sharma16 May 2020 1:35 PM IST

New Delhi: In a major breakthrough, drugmaker Zydus Cadila has received validation from the National Institute of Virology (NIV), Pune for...

Abbott rapid Covid-19 test potentially inaccurate, USFDA flags issue

Ruchika Sharma16 May 2020 12:33 PM IST

The researchers found that Abbott's test, run on the company's portable ID NOW system, missed one-third of the infections caught by Cepheid's test

NIPERs focuses on research, 3D products to fight COVID19

Ruchika Sharma16 May 2020 10:15 AM IST

NIPER-Raebareli has also initiated a mega project with IIT and an industrial partner in the development of new immuno-booster formulation utilizing...

Unichem Labs gets USFDA EIR for Roha API facility

Ruchika Sharma16 May 2020 10:00 AM IST

Mumbai: Unichem Laboratories Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration...

US likely to get first access to Sanofi Covid19 Vaccine: Bloomberg

Ruchika Sharma15 May 2020 6:14 PM IST

That's because the U.S. was first in line to fund Sanofi's vaccine research, Chief Executive Officer Paul Hudson said in an interview with Bloomberg...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok